🇺🇸 FDA
Patent

US 10543257

Lentiviral vector for treating hemoglobin disorders

granted A61KA61K38/42A61K48/005

Quick answer

US patent 10543257 (Lentiviral vector for treating hemoglobin disorders) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K38/42, A61K48/005